Sirtex Medical
Sirtex Medical Limited is a life-sciences company focused on developing and delivering innovative oncology treatments, primarily targeting liver cancer. The company is best known for its SIR-Spheres Y-90 resin microspheres, which are designed for selective internal radiation therapy (SIRT) to treat both primary and secondary metastatic liver cancer. Sirtex Medical employs novel small particle technology, utilizing biocompatible resin spheres containing a radioactive isotope that allows for targeted treatment directly to the liver. Headquartered in North Sydney, Australia, Sirtex Medical operates globally across the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. As of September 2018, it functions as a subsidiary of CDH Genetech Limited.
Nanospectra Biosciences, Inc. is a medical device company focused on developing and commercializing particle-based therapies for the selective thermal destruction of solid tumors. The company's flagship product, AuroLase Therapy, employs AuroShell particles, which include nanoshells and nanorods, to achieve precise thermal ablation while minimizing damage to surrounding healthy tissue. This innovative approach allows for effective treatment of various solid tumors with reduced side effects compared to conventional methods like surgery and radiation. Additionally, Nanospectra offers research-use-only nanoparticles with specific optical characteristics for medical and commercial applications. Founded in 2001 and based in Houston, Texas, the company aims to enhance treatment efficacy and improve patient outcomes through its advanced therapies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.